Day one- Wednesday 23 May

Day one- Wednesday 23 May ›

Wednesday 23 May- stream one ›

Wednesday 23 May 2012- stream two ›

Day Two: Thursday 24 May ›

last modified: 29 May '12

Please enable javascript to see more information on speakers

7.30am

Registration

8.20am

Opening remarks from the chair

8.30am

New approaches in de-risking candidate selection

Mark Graham

Mark Graham is Senior Principal Scientist and Global Discipline Leader for Discovery Safety. He has published more than 30 peer reviewed papers and many presentations and lectures at scientific conferences. Currently a member of the ‘Committee...

more..

Ways to optimize selection of low-risk candidate drugs will be discussed, with emphasis on:
• Comprehensive target safety review to inform target selection and balance portfolio risk
• Introducing predictive and high throughput safety methods to influence chemical design at lead generation stage
• Optimizing in vivo safety studies to support de-risked CD selection

› Mark Graham, Senior Principal Scientist, Safety Assessment, AstraZeneca R&D

8.55am

Why Invest in Biomarkers in Early Development

Vincenzo Teneggi at Biomarkers World Europe

› Vincenzo Teneggi, Head of Early Development and Clinical Pharmacology, Roche China

9.20am

Stimulating open innovation and collaborations in pharma

Andreas Wallnoefer

Roche Genentech R&D is driven by two autonomous R&D centers gRED, Genentech & pRED, Roche Pharma Research & Exploratory Development. Andreas Wallnoefer is the Global Head of pRED Development and is a member of the pRED Leadership Team. He is also...

more..

• The importance of translational medicine to enhance success rates in exploratory development
• The importance of industry/academia collaborations in translational sciences
• The role of personalized health care in R&D

› Andreas Wallnoefer, Global Head of pRED Development, F. Hoffmann- La Roche

9.45am

Grants for Targets - a novel open innovation initiative in drug discovery

Khusru Asadullah

Khusru Asadullah is Vice President and Head of Global Biomarker at Bayer HealthCare Pharmaceuticals. Before this he headed Target Discovery and Inflammation and Immunology research at Bayer Schering Pharma. He is a Professor of Medicine at the...

more..

› Khusru Asadullah, Vice President, Head of Global Biomarkers, Bayer Healthcare

10.10am

Design strategies for success in early phase trials

Nigel Dallow

Nigel Dallow is a Director of Clinical Statistics at GlaxoSmithKline supporting the respiratory area. Nigel has vast experience in working in drug development especially in the early phase area having worked at GSK for 17 years. Though his...

more..

•         Simulation approaches to optimise success
•         Increase use of mechanistic models as disease understanding increases.
•         Increase use of Pharmacometrics
•         Improving decision making through design.
•         Effective use of biomarkers.
•         Minimising missing data and consequences of avoiding issues.
•         Adaptive Design